

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
British Columbia Cancer Agency Branch	09/13/2005
RECEIVING PARTY DATA	
Name:	Public Health Agency of Canada through the National Microbiology Laboratory
Street Address:	1015 Arlington Street
City:	Winnipeg
State/Country:	CANADA
Postal Code:	R3E 3R2
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	60465783
Application Number:	60466733
PCT Number:	CA0400626
CORRESPONDENCE DATA	
Fax Number:	(617)345-1300
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6173451367
Email:	mstembridge@nixonpeabody.com
Correspondent Name:	Leena H. Karttunen Contarino
Address Line 1:	Nixon Peabody LLP
Address Line 2:	100 Summer Street
Address Line 4:	Boston, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	030481-054132
NAME OF SUBMITTER:	Megan L. Stembridge

Total Attachments: 2

source=83651-2 2010NOV18 Assignment from BCCAt to Public Health Ag. of CA#page1.tif

PATENT

501357604

REEL: 025391 FRAME: 0383

CH \$120.00 60465783

COPY

ASSIGNMENT

WHEREAS, the British Columbia Cancer Agency Branch ("BCCA") whose full post office address is 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6, Canada, has contributed to the developments relating to the SARS Virus Nucleotide and Amino Acid Sequences and Uses Thereof, and who's inventorship in the developments relating to the SARS Virus Nucleotide and Amino Acid Sequences and Uses Thereof, including the developments disclosed in U.S. Provisional Application Nos. 60/465,783 and 60/466,733, International Application No PCT/CA2004/000626, International Publication Number: WO 2004/096842, is yet to be determined;

AND WHEREAS, BCCA for good and valuable consideration, the receipt and sufficiency of which is acknowledged, does hereby sell, transfer and assign (respectively) to the Public Health Agency of Canada through the National Microbiology Laboratory (the "Assignee"), whose full post office address is 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2, all interest in the invention(s), if any, and developments relating to the SARS Virus Nucleotide and Amino Acid Sequences and Uses Thereof, including the invention(s) and developments disclosed in U.S. Provisional Application Nos. 60/465,783 and 60/466,733, International Application No PCT/CA2004/000626, International Publication Number: WO 2004/096842 and hereby grants to the Assignee all right, title and interest in any and all intellectual property therein, including any and all patents or applications (including reissues, conversions, divisions, renewals or extensions of such patents) or utility models, in any country, together with the right to claim priority to any such applications; and covenants that it has full right to convey the entire interest herein assigned, and that BCCA has not executed and will not execute any agreement in conflict herewith;

AND WHEREAS, BCCA agrees to do any reasonable act required to aid the Assignee, its successors, assigns and legal representatives to obtain and enforce title and proper legal protection for said invention(s) and developments in any country; and BCCA covenants that it will, execute and deliver all such papers as may be necessary to perfect title to said invention(s) and developments, and any future improvement(s) thereto, in the Assignee(s), its successors, assigns, nominees or legal representatives, when reasonably required to do so; and BCCA agrees to communicate to the Assignee(s), or its nominees, all facts respecting said invention(s) and developments, and any future improvement(s) thereto, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all oaths, and generally make reasonable efforts to aid the Assignee, its successors, assigns, nominees and legal representatives when such efforts are required to obtain and enforce for its own benefit, proper patent or other intellectual property protection for said invention(s) and developments in any and all countries, all at the expense, however, of the Assignee(s) or its successors, assigns, nominees or legal representatives; and the Assignee(s) or its successors, assigns, nominees or legal representatives will make best efforts to minimise the burden posed in meeting these requirements .


EXECUTED at Vancouver, BC
this 15th day of September, 2005.



Samuel Abraham, Ph.D.
Director, Technology Development

STATEMENT OF WITNESS

On this 15th day of September, 2005, before me, personally appeared Samuel Abraham known to me to be the individual who executed the foregoing instrument.


Signature of Witness

Print name of witness: CANDACE BINGHAM